A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
Abroad (travel likely)RecruitingPHASE1
Conditions
Alzheimer Disease, Early Onset
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Clinical Site(s), 's-Hertogenbosch, Netherlands
Clinical Site(s), Amsterdam, Netherlands
Clinical Site(s), Zwolle, Netherlands
Clinical Site(s), London, United Kingdom
Study leads
Medical Monitor
Study Director
Denali Therapeutics